Theratechnologies Inc.

Toronto Stock Exchange TH.TO

Theratechnologies Inc. EPS (Diluted) for the year ending November 30, 2023: USD -0.91

Theratechnologies Inc. EPS (Diluted) is USD -0.91 for the year ending November 30, 2023, a -82.00% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.
  • Theratechnologies Inc. EPS (Diluted) for the year ending November 30, 2022 was USD -0.50, a -47.06% change year over year.
  • Theratechnologies Inc. EPS (Diluted) for the year ending November 30, 2021 was USD -0.34, a -17.24% change year over year.
  • Theratechnologies Inc. EPS (Diluted) for the year ending November 30, 2020 was USD -0.29, a -26.09% change year over year.
  • Theratechnologies Inc. EPS (Diluted) for the year ending November 30, 2019 was USD -0.23, a -285.91% change year over year.
Key data
Date EPS (Diluted) Shares (Diluted, Weighted) Shares (Basic, Weighted) Revenue
Market news
SV Wall Street
Toronto Stock Exchange: TH.TO

Theratechnologies Inc.

CEO Mr. Paul Lévesque
IPO Date Aug. 6, 1996
Location Canada
Headquarters 2015 Peel Street
Employees 103
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines
Description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

StockViz Staff

February 6, 2025

Any question? Send us an email